Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib Adaptive Therapy Guided by ctDNA in EGFR-mutated NSCLC
NCT07661173Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Anhui Provincial Tumor Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07661173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661173.